Sectoral Asset Management Inc. cut its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 92.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,955 shares of the company’s stock after selling 167,240 shares during the quarter. Sectoral […]
Sectoral Asset Management Inc. cut its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 92.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,955 shares of the company’s stock after selling 167,240 shares during the quarter. Sectoral […]
PALO ALTO, Calif., June 03, 2024 BridgeBio Pharma, Inc. , a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that members of its management team, along.
Early Increase in Serum Transthyretin Level Is an Independent Predictor of Improved Survival in ATTR Cardiomyopathy: Insights From Acoramidis Phase 3 Study ATTRibute-CM .